Use of surgery and electron beam irradiation, with or without chemotherapy, for treatment of vaccine-associated sarcomas in cats: 78 cases (1996–2000)

Cohen, Michele; Wright, James C.; Brawner, William R.; Smith, Annette; Henderson, Ronald D.; Behrend, Ellen N.

doi:10.2460/javma.2001.219.1582

Cited by 90 publications

(144 citation statements)

References 10 publications

Supporting

Mentioning

115

Contrasting

Unclassified

Order By: Relevance

“…Local excision ('lumpectomy') of FISS is not recommended. In addition to surgery, radiation therapy and/or chemotherapy may be recommended based on consultation with an oncologist [71][72][73][74][75] FISS = feline injection-site sarcoma, SC = subcutaneous, IM = intramuscular Table 6 Indications for the use of inactivated vaccines in cats also other factors that may influence the choice of live versus inactivated vaccines (see Table 6 and Appendix 1 [General FAQs],…”

Section: Remove Tumor Surgicallymentioning

confidence: 99%

2013 AAFP Feline Vaccination Advisory Panel Report

Scherk¹,

Ford

Gaskell

et al. 2013

Journal of Feline Medicine and Surgery

121

111

View full text Add to dashboard Cite

Section: Remove Tumor Surgicallymentioning

confidence: 99%

2013 AAFP Feline Vaccination Advisory Panel Report

Scherk¹,

Ford

Gaskell

et al. 2013

Journal of Feline Medicine and Surgery

121

111

View full text Add to dashboard Cite

“…The metastatic rate of FISS varies from 10% in more recent studies, to 25% in older reports, with a much higher incidence compared to sarcomas that are not associated with vaccinations [8,12,[14][15][16]. Generally, FISS metastasize to the lungs, but other locations were also reported, such as regional lymph nodes, mediastinum, liver and omentum [8,11,17,18].…”

Section: Discussionmentioning

confidence: 99%

Description of a Feline Injection-Site Fibrosarcoma with Metastasis in the Cerebellum

et al. 2017

View full text Add to dashboard Cite

Feline injection-site sarcomas were initially described by Hendrick and Goldschmidt (1991). The link between vaccination site and sarcoma occurrence suggested the term of vaccine-associated sarcomas. Our paper describes an unusual feline injection-site fi brosarcoma with cerebellar metastasis. A 7-year-old female domestic short-hair cat was submitted to the Pathology Department (Faculty of Veterinary Medicine ClujNapoca, Romania) for necropsy. A subcutaneous tumor (relapse) in the interscapular region and multiple metastatic masses in the lungs, kidneys, subcutaneous tissue (scapular and thigh regions) and cerebellum were observed. Cytological, histological and immunohistochemical (for vimentin, desmin, multi-cytokeratin, α-smooth muscle actin, S100 and CD45) analyses from all tumors were performed. Cytological examination identifi ed highly pleomorphic spindle-shaped cells admixed with neoplastic multinucleated giant cells. Histologically, all neoplastic masses were composed of numerous spindle cells arranged into interlacing bundles. Extensive intratumoral areas of necrosis along with a neutrophilic infi ltrate were also detected. A fi brillary material was present among neoplastic cells (green stained by Masson's trichrome method), suggesting a collagenous structure. In all tumors assessed, immunohistochemistry showed an intense reaction only for vimentin in numerous neoplastic cells. Based on the history, gross, cytological, histological and immunohistochemical data, the fi nal diagnosis was recurrent feline injection-site fi brosarcoma, with multiple metastases (including in the cerebellum). Overall, an uncommon case of feline injection-site fi brosarcoma has been reported. This is the fi rst consistent record of an injection site sarcoma in a cat with cerebellar metastasis.

show abstract

“…Cohen et al 4 stated that the location and the size of the primary tumor and the ability to remove it are important prognostic factors. The recurrence rate in the present study could have been influenced by the fact that most of the cats had small tumors and that the surgical procedure was performed by an experienced surgeon.…”

Section: Discussionmentioning

confidence: 99%

“…8,9 Pre-or postoperative radiation therapy extends the median tumor-free time up to 422 days 10 and may reduce the recurrence rate to 42% in cats with clean surgical margins. 11 In the study by Cohen et al, 4 a recurrence rate of 41% after tumor excision, electron-beam radiation, and, in some cases, chemotherapy was documented. Chemotherapy regimens that have been investigated include doxorubicin 12,13 and carboplatin.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Adjuvant Immunotherapy of Feline Fibrosarcoma with Recombinant Feline Interferon-ω

Hampel¹,

Schwarz

Kempf

et al. 2007

J Vet Int Med

View full text Add to dashboard Cite

Background: Recombinant feline interferon-v (rFeIFN-v) was tested as a treatment option for cats with fibrosarcoma to assess safety and feasibility.Hypothesis: Treatment with rFeIFN-v in cats with fibrosarcoma is safe and feasible. Animals: Twenty domestic cats. Methods:In an open-labeled uncontrolled clinical trial 12 injections of 1 3 10 6 U/kg rFeIFN-v were administered over a 5-week period: the 1st through 4th injections were given intratumorally, and the 5th through 12th injections were administered subcutaneously at the tumor excision site. Wide surgical excision of the tumors was carried out after the 4th injection and before the 5th injection of rFeIFN-v. A Common Terminology Criteria for Adverse Events (CTCAE) analysis was conducted. Flow cytometry of fibrosarcoma cells after incubation with rFeIFN-v and recombinant feline interferon-c was performed to assess the biological effect of rFeIFN-v.Results: Changes in blood cell count, increases in serum aspartate-amino-transferase activity, serum bilirubin concentration, serum creatinine and serum electrolyte concentrations, weight loss, anorexia, increased body temperature, and reduced general condition were observed but were mostly minor (grade 1 and 2) and self limiting. Eosinophilia (P 5 .025), neutropenia (P 5 .021), and weight loss (P , .001) were statistically correlated with rFeIFN-v-treatment (analysis of parameters before treatment and after 3 injections of rFeIFN-v). Flow cytometry of 5 unrelated feline fibrosarcoma cell lines showed increased expression of major histocompatibility complex (MHC) class I molecules (P 5 .026) in response to in vitro incubation with rFeIFN-v, whereas expression of MHC class II molecules was not affected significantly.Conclusions and Clinical Importance: RFeIFN-v for the treatment of feline fibrosarcoma is safe, well tolerated, and can be easily performed in practice. To assess the efficacy of the treatment, it should be tested in a placebo-controlled trial.

show abstract

Use of surgery and electron beam irradiation, with or without chemotherapy, for treatment of vaccine-associated sarcomas in cats: 78 cases (1996–2000)

Abstract: Results suggest that excision followed by electron beam irradiation may be beneficial for treatment of cats with vaccine-associated sarcomas. Extent of excision prior to radiotherapy did not seem to be associated with recurrence rate.

Cited by 90 publications

References 10 publications

2013 AAFP Feline Vaccination Advisory Panel Report

2013 AAFP Feline Vaccination Advisory Panel Report

Description of a Feline Injection-Site Fibrosarcoma with Metastasis in the Cerebellum

Adjuvant Immunotherapy of Feline Fibrosarcoma with Recombinant Feline Interferon-ω

Contact Info

Product

Resources

About